Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Nov;75(11):1917-1923.
doi: 10.1136/annrheumdis-2015-208426. Epub 2016 Jan 5.

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)

Yuko Kaneko  1 , Tatsuya Atsumi  2 , Yoshiya Tanaka  3 , Masayuki Inoo  4 , Hitomi Kobayashi-Haraoka  5 , Koichi Amano  6 , Masayuki Miyata  7 , Yohko Murakawa  8 , Hidekata Yasuoka  1 , Shintaro Hirata  3 , Hayato Nagasawa  6 , Eiichi Tanaka  9 , Nobuyuki Miyasaka  10 , Hisashi Yamanaka  9 , Kazuhiko Yamamoto  11 , Tsutomu Takeuchi  1
Affiliations
Randomized Controlled Trial

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)

Yuko Kaneko et al. Ann Rheum Dis. 2016 Nov.

Abstract

Objective: To compare the efficacy and safety between tocilizumab added to methotrexate and tocilizumab switched from methotrexate in patients with active rheumatoid arthritis (RA).

Methods: This is a 2-year randomised, controlled study. RA patients with moderate or high disease activity despite methotrexate were randomly assigned either to tocilizumab added to methotrexate (add-on) or tocilizumab switched from methotrexate (switch). The primary endpoint was the DAS28 remission rate at week 24. Secondary objectives included other clinical efficacy indices, radiological outcomes assessed with the van der Heijde-modified total Sharp scoring system (mTSS), and safety.

Results: Of 223 randomised patients, 83% completed 52 weeks. DAS28 remission rates at week 24 were 70% for add-on and 55% for switch (p=0.02), but they became comparable at week 52 (72% vs 70%, p=0.86). Structural remission rates (mTSS≤0.5) at week 52 were not different (66% vs 64%, p=0.92). However, clinically relevant radiographic progression rates (CRRP; mTSS≥3) tended to be higher with the switch than with the add-on (15% vs 7%, p=0.07). Radiographic progression in the CRRP patients was larger with the switch than with the add-on (9.0/year vs 5.0/year, p=0.04). The difference in the mean C-reactive protein of the CRRP patients was significant for the first 24 weeks (1.56 vs 0.49, p=0.001) but not for the following 28 weeks (0.10 vs 0.04, p=0.1). Overall safety was preferable in the switch group.

Conclusions: In RA patients with inadequate response to methotrexate, tocilizumab added to methotrexate more rapidly suppressed inflammation than tocilizumab switched from methotrexate, leading to superior clinical efficacy and prevention of joint destruction.

Trial registration number: NCT01120366.

Keywords: DMARDs (biologic); Disease Activity; Rheumatoid Arthritis; Treatment.

PubMed Disclaimer

Conflict of interest statement

YK has received lecture fees from AbbVie GK, Eisai Co, Chugai Pharmaceutical Co, Eli Lilly Japan K.K., Mitsubishi-Tanabe, Bristol–Myers K.K., Astellas Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Pfizer, Janssen, Santen, Kyowa Hakko Kirin and UCB Japan. TA has received research grants or lecture fees from Eisai Co, Chugai Pharmaceutical Co, Novartis, Mitsubishi-Tanabe, Teijin, Astellas, Takeda, Novo Nordisk, Abbvie GK, Pfizer and Bristol–Myers K.K. YT has received consulting fees, speaking fees and/or honoraria from Abbvie GK, Daiichi-Sankyo, Chugai Pharmaceutical Co, Takeda, Mitsubishi-Tanabe, Bristol–Myers K.K., Astellas, Eisai Co, Janssen, Pfizer, Asahikasei Pharma Corp., Eli Lilly Japan K.K., GlaxoSmithKline, UCB Japan, Teijin, MSD and Santen and has received research grants from Mitsubishi-Tanabe, Takeda, Chugai Pharmaceutical Co, Astellas, Eisa Co.i, Taisho-Toyama, Kyowa-Kirin, AbbVie GK and Bristol–Myers K.K. KA has received research grants from Chugai Pharmaceutical Co. and Astellas, and has received lecture fees from Abbvie GK, Astellas, Bristol–Myers K.K., Chugai Pharmaceutical Co and Pfizer. SH has received lecture fees from AbbVie GK, Eisai Co an Bristol–Myers K.K. YM has received research grants or lecture fees from Japan Blood Products, Taisho Toyama, Nippon Kayaku, Takeda Pharma, AbbVie GK, Janssen Pharma. and UCB Japan, Astellas, Chugai Pharmaceutical Co, Ono, Mitsubishi-Tanabe, Teijin and Eisai Co. SH has received lecture fees from AbbVie GK, Eisai and Bristol-Myers K.K. ET has received lecture fees or consulting fees from Abbvie GK, Eisai Co, Chugai Pharmaceutical Co, Bristol–Myers K.K., Astellas Pharmaceutical, Pfizer, Takeda Pharmaceutical and Santen Pharmaceutical. HY has received research grants or lecture fees from AbbVie GK, Bristol-Myers K.K., Chugai Pharmaceutical Co, Eisai Co, Mitsubishi-Tanabe, Astellas, Pfizer, Takeda, UCB Japan and Nippon Shinyaku. KY has received consultancy fees from Abbott, Bristol-Myers K.K., Chugai Pharmaceutical Co, Eisai Co, Mitsubishi-Tanabe, Pfizer, Roche and UCB Pharma, and has received research grants from AbbVie GK, Eisai Co, Mitsubishi-Tanabe, Pfizer, Santen and UCB Japan. TT has received research grants or lecture fees from Astellas Pharma, Bristol-Myers K.K., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahikasei Pharma Corp., Taisho Toyama Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Ltd., Janssen Pharmaceutical K.K., Celtrion, Nipponkayaku Co. Ltd. and UCB Japan, and consultant fees from Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Co., Asahi Kasei Medical K.K., Abbvie GK, Daiichi Sankyo Co., Ltd., Bristol–Myers K.K. and Nipponkayaku Co. Ltd.

Figures

Figure 1
Figure 1
Patient disposition and study flow chart. IC, informed consent.
Figure 2
Figure 2
Clinical efficacy results. Results over time for (A) percentage of patients achieving DAS28 remission, (B) percentage of patients achieving ACR20/50/70, (C) patients achieving remission according to DAS28, SDAI, CDAI and ACR/EULAR Boolean defined criteria at weeks 24 and 52. DAS28, disease activity score for 28 joints; ACR, American College of Rheumatology; SDAI, simplified disease activity index; CDAI, clinical disease activity index; EULAR, European League against Rheumatism. *p<0.05.
Figure 3
Figure 3
Structural outcome. (A) Cumulative probability plot of change from baseline to week 52 in van der Heijde-modified total Sharp scoring system (mTSS). (B) Percentage of patients with CRRP. (C) Mean CRP. CRRP, clinically relevant radiographic progression; DAS28, disease activity score for 28 joints; CRP, C-reactive protein. *p<0.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Smolen JS, Landewé R, Breedveld FC, et al. . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509. 10.1136/annrheumdis-2013-204573 - DOI - PMC - PubMed
    1. Smolen JS, Aletaha D, Bijlsma JW, et al. , T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7. 10.1136/ard.2009.123919 - DOI - PMC - PubMed
    1. Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med 2011;60:75–81. 10.2302/kjm.60.75 - DOI - PubMed
    1. Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug? Autoimmun Rev 2014;13:1102–8. 10.1016/j.autrev.2014.08.026 - DOI - PubMed
    1. Klareskog L, van der Heijde D, de Jager JP, et al. , TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81. 10.1016/S0140-6736(04)15640-7 - DOI - PubMed

Publication types

Associated data